SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIBPRNewsWire • 03/11/24
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological ConditionsBusiness Wire • 03/11/24
Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's TreatmentInvestors Business Daily • 03/08/24
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyGlobeNewsWire • 03/06/24
Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) 2024 Annual MeetingGlobeNewsWire • 03/04/24
Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript)Seeking Alpha • 03/04/24
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?The Motley Fool • 03/02/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of InvestorsBusiness Wire • 02/23/24
Biogen's QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPGlobeNewsWire • 02/23/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of InvestorsBusiness Wire • 02/22/24
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of InvestorsBusiness Wire • 02/22/24
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 EarningsZacks Investment Research • 02/13/24
Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatmentMarket Watch • 02/13/24
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapiesCNBC • 02/13/24